Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lifestream cholesterol test

This article was originally published in The Tan Sheet

Executive Summary

Lifestream Technologies receives FDA 510k clearance to market consumer cholesterol test incorporating Health Risk Assessment technology, enabling users to track cholesterol levels as well as personal risk of heart attack and obesity. Users can obtain a Health Risk Assessment profile after taking a three-minute cholesterol test and entering additional risk factors, including diabetic status, systolic and diastolic blood pressure and HDL-C break-out from a recent lipid profile. The test will be available to consumers through the firm's 1website in late June and move to other distribution channels later this year. McNeil recently announced a licensing agreement with International Medical Innovations to develop and market the PREVU(x) consumer cholesterol test (2"The Tan Sheet" June 7, 2004, p. 10)...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS096933

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel